Promising vaccine could treat two deadliest and fastest-rising forms of cancer, early study shows

Promising vaccine could treat two deadliest and fastest-rising forms of cancer, early study shows An off-the-shelf cancer vaccine could help prevent relapse in patients with two of the deadliest and fastest-rising cancers in the world.

The shot is designed for patients whose cancers are caused by the KRAS mutation, which accounts for up to nine in 10 cases of the disease. 

An early trial tested the effects in people with colon and pancreatic cancers. The first-in-human study found the vaccine, developed by the small firm Elicio Therapeutics, showed the potential to lower the risk of relapse in 100 percent of patients who had surgery to remove their tumors but still had cancer markers in their blood. The Daily Mail

See also:

• Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting Elicio Therapeutics